logo
Twitter
Discord
Email
logo
AnaptysBio, Inc.

AnaptysBio, Inc.

NASDAQ•ANAB
CEO: Mr. Daniel R. Faga
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2017-01-26
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Contact Information
10770 Wateridge Circle, Suite 210, San Diego, CA, 92121-5801, United States
858-362-6295
www.anaptysbio.com
Market Cap
$1.26B
P/E (TTM)
-15.7
38.2
Dividend Yield
--
52W High
$52.47
52W Low
$12.21
52W Range
83%
Rank60Top 89.2%
2.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$76.32M+154.26%
4-Quarter Trend

EPS

$0.54-147.37%
4-Quarter Trend

FCF

-$27.37M+170.30%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Collaboration Revenue Surges Nine months collaboration revenue reached $126.4M, a 162% increase from $48.2M recognized in the prior nine months.
Net Loss Significantly Narrows Nine months net loss improved to $62.8M, substantially reduced from the $123.4M net loss reported last year.
R&D Expenses Decline Total R&D expenses decreased by $10.9M to $110.4M for nine months, driven by lower external development costs.
Stock Repurchase Program Active Company spent $65.2M repurchasing common stock under the authorized $75.0M 2025 Repurchase Program through September 30.

Risk Factors

Future Financing Needs Critical Limited operating revenue history necessitates additional capital raises, risking dilution or unfavorable financing terms.
Clinical Trial Execution Risk Success depends on favorable outcomes and timely enrollment in ongoing Phase 2 trials for Rosnilimab (UC) and ANB033 (CeD).
Stockholder Dilution Potential Future equity issuances, including incentive plans, could materially dilute existing stockholders and depress stock price.
Manufacturing Supply Chain Risk Reliance on third-party manufacturers for complex biologics introduces risks of delays or supply interruptions.

Outlook

Planned Company Separation Board approved separating into Biopharma Co and Royalty Co, with separation completion targeted by year-end 2026.
Rosnilimab UC Data Anticipated Expect reporting top-line Phase 2 data for the rosnilimab ulcerative colitis trial in November or December 2025.
ANB033 Celiac Data Due Anticipate reporting top-line Phase 1b data from the ANB033 Celiac Disease trial by the fourth quarter of 2026.
Cash Runway Assessment Current cash funds operating plan for at least 12 months, but future capital requirements remain substantial.

Peer Comparison

Revenue (TTM)

Maravai LifeSciences Holdings, Inc.MRVI
$192.28M
-30.6%
AnaptysBio, Inc.ANAB
$169.47M
+196.4%
Xencor, Inc.XNCR
$167.36M
+64.5%

Gross Margin (Latest Quarter)

Xencor, Inc.XNCR
100.0%
+17.2pp
Tango Therapeutics, Inc.TNGX
99.0%
-1.0pp
Phathom Pharmaceuticals, Inc.PHAT
87.5%
+1.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TNGX$1.44B-14.4-60.8%16.5%
PGEN$1.32B-5.3-3342.6%57.3%
ANAB$1.26B-15.7-1101.2%98.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
21.0%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 26, 2026
|
EPS:$0.89
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 4, 2025|
    Revenue: $76.32M+154.3%
    |
    EPS: $0.54-147.4%
    Beat
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $22.26M+102.9%
    |
    EPS: $-1.34-21.6%
    Beat
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 5, 2025|
    Revenue: $27.77M+286.8%
    |
    EPS: $-1.28-22.0%
    Beat
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 27, 2025|
    Revenue: $91.28M+432.0%
    |
    EPS: $-5.12+15.8%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 5, 2024|
    Revenue: $30.02M+804.7%
    |
    EPS: $-1.14-19.1%
    Beat
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 5, 2024|
    Revenue: $10.97M+217.1%
    |
    EPS: $-1.71+14.0%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 9, 2024|
    Revenue: $7.18M+422.5%
    |
    EPS: $-1.64-5.2%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 11, 2024|
    Revenue: $17.16M+66.8%
    |
    EPS: $-6.08-33.0%
    Miss